Alerian MLP Index ETNs due January 28 2044 (AMJB) Financials

AMJB

Trailing 12 months to June 30, 2026

Revenue $199.4B +13.5% YoY

Net Income $65.0B +15.0% YoY

EPS (Diluted) $23.35 +19.8% YoY

Operating Cash Flow -$162.5B -9.4% YoY

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 6, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the AMJB SEC filings page.

Alerian MLP Index ETNs due January 28 2044 (AMJB) reported $199.4B in revenue over the twelve months to Jun 30, 2026, up 13.5% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI AMJB FY2025 2026-10-03

The reported accounts describe a highly leveraged financial vehicle, not a conventional operating business funded by sales and costs.

The latest two years separate reported earnings from cash generation: net income stayed positive at $58.5B in FY2024 and $57.0B in FY2025, while operating cash flow moved from -$42.0B to -$147.8B. At the same time, assets expanded by roughly $422.1B, indicating that balance-sheet growth was not funded by internally generated cash.

From FY2021 through FY2025, reported total assets increased from $3.7T to $4.4T, while net income moved from $48.3B to $57.0B. That combination suggests the statements are dominated by changes in the vehicle’s holdings and financing structure, rather than a normal sales-and-cost cycle.

FY2025 liabilities were $4.1T against $362.4B of equity, with reported leverage at 11.2x; equity therefore represents a relatively thin layer beneath obligations. Financing cash flow of $269.5B alongside operating cash flow of -$147.8B shows that reported funding flows, rather than operating earnings, drove much of the period’s cash movement.

Financial Health Signals

Financial health score not available

Alerian MLP Index ETNs due January 28 2044 does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

2/6

Alerian MLP Index ETNs due January 28 2044 passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, all 1 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality No Cash Backing

$2.59used

For every $1 of reported earnings, Alerian MLP Index ETNs due January 28 2044 used $2.59 of operating cash (-$147.8B OCF vs $57.0B net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$57.3B

YoY+27.7%

QoQ+15.1%

5Y CAGR+13.5%

10Y CAGR+8.9%

Alerian MLP Index ETNs due January 28 2044 generated $57.3B in revenue in Q2 2026. This represents an increase of 27.7% from the same quarter a year earlier. Against the prior quarter it is up 15.1%.

Net Income

$21.2B

YoY+41.2%

QoQ+28.3%

5Y CAGR+12.1%

10Y CAGR+13.1%

Alerian MLP Index ETNs due January 28 2044 reported $21.2B in net income in Q2 2026. This represents an increase of 41.2% from the same quarter a year earlier. Against the prior quarter it is up 28.3%.

EPS (Diluted)

$7.70

YoY+46.9%

QoQ+29.6%

5Y CAGR+15.3%

10Y CAGR+17.4%

Alerian MLP Index ETNs due January 28 2044 earned $7.70 per diluted share (EPS) in Q2 2026. This represents an increase of 46.9% from the same quarter a year earlier. Against the prior quarter it is up 29.6%.

EBITDA

Not reported for Q2 2026.

Cash & Balance Sheet

Cash & Debt

$309.8B

YoY-26.3%

QoQ-0.7%

5Y CAGR-15.2%

Alerian MLP Index ETNs due January 28 2044 held $309.8B in cash as of Q2 2026; long-term debt is not reported for that period.

Dividends Per Share

$1.50

YoY+7.1%

QoQ0.0%

5Y CAGR+10.8%

10Y CAGR+12.1%

Alerian MLP Index ETNs due January 28 2044 paid $1.50 per share in dividends in Q2 2026. This represents an increase of 7.1% from the same quarter a year earlier. It is unchanged from the prior quarter.

Shares Outstanding

2.66B

YoY-3.3%

QoQ-0.8%

5Y CAGR-2.3%

10Y CAGR-3.0%

Alerian MLP Index ETNs due January 28 2044 had 2.66B shares outstanding in Q2 2026. This represents a decrease of 3.3% from the same quarter a year earlier. Against the prior quarter it is down 0.8%.

Free Cash Flow

Not reported for Q2 2026.

Margins & Returns

Net Margin

36.9%

YoY+3.5pp

QoQ+3.8pp

5Y change-2.3pp

10Y change+11.5pp

Alerian MLP Index ETNs due January 28 2044's net profit margin was 36.9% in Q2 2026, showing the share of revenue converted to profit. This is up 3.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 3.8 percentage points.

Return on Equity

5.7%

YoY+1.4pp

QoQ+1.1pp

5Y change+1.5pp

10Y change+3.2pp

Alerian MLP Index ETNs due January 28 2044's ROE was 5.7% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 1.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.1 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Capital Allocation

Share Buybacks

$6.8B

YoY-9.6%

QoQ-18.5%

5Y CAGR+1.8%

Alerian MLP Index ETNs due January 28 2044 spent $6.8B on share buybacks in Q2 2026, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 9.6% from the same quarter a year earlier. Against the prior quarter it is down 18.5%.

R&D Spending

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

AMJB Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

AMJB quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$199.4B	$182.4B+2.8%	$177.6B+12.3%	$158.1B+22.9%	$128.7B+5.8%	$121.6B+1.4%	$120.0B+3.7%	$115.7B+6.4%	$108.8B+8.0%	$100.7B+4.3%	$96.6B+3.2%	$93.5B-1.6%	$95.1B-2.3%	$97.4B+0.3%	$97.0B-0.2%	$97.2B
SG&A Expenses	$57.2B	$54.5B+6.1%	$51.4B+10.5%	$46.5B+11.6%	$41.6B+8.0%	$38.6B+10.2%	$35.0B+2.4%	$34.2B+3.1%	$33.1B+6.1%	$31.2B+3.3%	$30.2B+1.5%	$29.8B-1.4%	$30.2B-2.1%	$30.8B+0.7%	$30.6B+5.3%	$29.0B
Interest Expense	$98.2B	$97.9B-3.4%	$101.3B+24.6%	$81.3B+211.6%	$26.1B+370.0%	$5.6B-44.2%	$10.0B-62.8%	$26.8B+27.3%	$21.0B+51.7%	$13.9B+41.3%	$9.8B+31.6%	$7.5B-5.5%	$7.9B-15.5%	$9.3B-15.3%	$11.0B-18.8%	$13.6B
Income Tax	$18.8B	$15.5B-6.4%	$16.6B+37.7%	$12.1B+42.0%	$8.5B-24.4%	$11.2B+68.0%	$6.7B-20.8%	$8.4B+1.7%	$8.3B-27.7%	$11.5B+16.9%	$9.8B+56.6%	$6.3B-30.1%	$9.0B+1.9%	$8.8B+15.1%	$7.6B-1.8%	$7.8B
Net Income	$65.0B	$57.0B-2.6%	$58.5B+17.9%	$49.6B+31.6%	$37.7B-21.9%	$48.3B+65.8%	$29.1B-20.0%	$36.4B+12.2%	$32.5B+32.9%	$24.4B-1.2%	$24.7B+1.2%	$24.4B+12.4%	$21.7B+21.6%	$17.9B-16.0%	$21.3B+12.2%	$19.0B
EPS (Basic)	N/A	$20.05+1.3%	$19.79+21.8%	$16.25+34.3%	$12.10-21.4%	$15.39+73.1%	$8.89-17.3%	$10.75+18.9%	$9.04+42.4%	$6.35+1.8%	$6.24+3.1%	$6.05+13.5%	$5.33+21.7%	$4.38-16.1%	$5.22+16.0%	$4.50
EPS (Diluted)	$23.35	$20.02+1.4%	$19.75+21.7%	$16.23+34.2%	$12.09-21.3%	$15.36+73.0%	$8.88-17.2%	$10.72+19.1%	$9.00+42.6%	$6.31+1.9%	$6.19+3.2%	$6.00+13.4%	$5.29+21.9%	$4.34-16.5%	$5.20+16.1%	$4.48
Diluted Shares (Avg)	N/A	2.78B-3.4%	2.88B-2.2%	2.94B-0.9%	2.97B-1.9%	3.03B-2.0%	3.09B-4.4%	3.23B-5.4%	3.41B-4.6%	3.58B-3.1%	3.69B-2.2%	3.77B-0.6%	3.80B-0.5%	3.81B-0.2%	3.82B-2.5%	3.92B

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$57.3B+27.7%	$49.8B+10.0%	$45.8B+7.1%	$46.4B+8.8%	$44.9B-10.5%	$45.3B+8.1%	$42.8B+10.9%	$42.7B+7.0%
SG&A Expenses	$15.2B+10.6%	$15.3B+8.8%	$13.1B+5.2%	$13.6B+5.8%	$13.7B+5.8%	$14.1B+7.4%	$12.5B+5.3%	$12.8B+9.3%
Interest Expense	$25.1B+0.3%	$23.8B+1.0%	$23.8B-1.7%	$25.5B-5.7%	$25.0B-2.9%	$23.6B-3.2%	$24.2B+3.8%	$27.0B+23.7%
Income Tax	$6.4B+92.9%	$4.0B+5.8%	$4.1B+22.7%	$4.3B+6.6%	$3.3B-37.6%	$3.8B-2.8%	$3.4B+66.9%	$4.1B+13.9%
Net Income	$21.2B+41.2%	$16.5B+12.6%	$13.0B-7.5%	$14.4B+11.6%	$15.0B-17.4%	$14.6B+9.1%	$14.0B+50.0%	$12.9B-1.9%
EPS (Basic)	$7.71+46.9%	$5.95+17.1%	$4.64-3.7%	$5.08+16.0%	$5.25-14.4%	$5.08+14.2%	$4.82+58.0%	$4.38+1.2%
EPS (Diluted)	$7.70+46.9%	$5.94+17.2%	$4.64-3.5%	$5.07+16.0%	$5.24-14.4%	$5.07+14.2%	$4.81+57.7%	$4.37+0.9%
Diluted Shares (Avg)	2.69B-3.6%	2.72B-3.7%	N/A	2.77B-3.4%	2.79B-3.5%	2.82B-3.0%	N/A	2.87B-2.3%

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses, Operating Income, EBITDA.

AMJB Balance Sheet

AMJB quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$4.4T+10.5%	$4.0T+3.3%	$3.9T+5.7%	$3.7T-2.1%	$3.7T+10.6%	$3.4T+26.0%	$2.7T+2.4%	$2.6T+3.5%	$2.5T+1.7%	$2.5T+5.9%	$2.4T-8.6%	$2.6T+6.5%	$2.4T+2.4%	$2.4T+4.1%	$2.3T
Cash & Equivalents	$343.3B-26.8%	$469.3B-24.8%	$624.2B+10.0%	$567.2B-23.4%	$740.8B+40.4%	$527.6B+100.1%	$263.6B-5.4%	$278.8B-35.4%	$431.3B+10.3%	$391.2B+8.1%	$361.7B	N/A	N/A	N/A	N/A
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	N/A	N/A	N/A	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	N/A	N/A	N/A	N/A
Goodwill	$52.7B+0.3%	$52.6B-0.1%	$52.6B+1.9%	$51.7B+2.7%	$50.3B+2.2%	$49.2B+3.0%	$47.8B+0.7%	$47.5B-0.1%	$47.5B+0.5%	$47.3B-0.1%	$47.3B-0.7%	$47.6B-0.9%	$48.1B-0.2%	$48.2B0.0%	$48.2B
Total Liabilities	$4.1T+11.1%	$3.7T+3.1%	$3.5T+5.2%	$3.4T-2.2%	$3.4T+11.1%	$3.1T+28.0%	$2.4T+2.5%	$2.4T+3.9%	$2.3T+1.8%	$2.2T+6.3%	$2.1T-10.1%	$2.3T+6.2%	$2.2T+2.3%	$2.2T+3.5%	$2.1T
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$267.9B+7.6%	$249.0B-3.0%	$256.8B
Total Equity	$362.4B+5.1%	$344.8B+5.1%	$327.9B+12.2%	$292.3B-0.6%	$294.1B+5.3%	$279.4B+6.9%	$261.3B+1.9%	$256.5B+0.3%	$255.7B+0.6%	$254.2B+2.7%	$247.6B+6.8%	$231.7B+9.7%	$211.2B+3.5%	$204.1B+11.2%	$183.6B
Retained Earnings	$416.1B+10.6%	$376.2B+13.0%	$332.9B+12.3%	$296.5B+8.9%	$272.3B+14.9%	$237.0B+6.2%	$223.2B+12.1%	$199.2B+12.1%	$177.7B+9.4%	$162.4B+10.9%	$146.4B+12.7%	$130.0B+12.3%	$115.8B+11.1%	$104.2B+18.0%	$88.3B

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$5.0T+10.2%	$4.9T+12.5%	$4.4T+10.5%	$4.6T+8.3%	$4.6T+9.9%	$4.4T+6.5%	$4.0T+3.3%	$4.2T+8.0%
Cash & Equivalents	$309.8B-26.3%	$312.1B-26.7%	$343.3B-26.8%	$303.4B-30.1%	$420.3B-20.8%	$425.9B-24.2%	$469.3B-24.8%	$434.3B-15.1%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$52.7B-0.1%	$52.7B+0.2%	$52.7B+0.3%	$52.7B0.0%	$52.7B+0.2%	$52.6B0.0%	$52.6B-0.1%	$52.7B+0.4%
Total Liabilities	$4.6T+10.6%	$4.5T+13.2%	$4.1T+11.1%	$4.2T+8.7%	$4.2T+10.3%	$4.0T+6.7%	$3.7T+3.1%	$3.9T+7.9%
Total Equity	$374.6B+5.0%	$364.0B+3.6%	$362.4B+5.1%	$360.2B+4.2%	$356.9B+4.8%	$351.4B+4.4%	$344.8B+5.1%	$345.8B+9.0%
Retained Earnings	$445.0B+12.0%	$428.2B+10.8%	$416.1B+10.6%	$407.4B+11.3%	$397.4B+11.3%	$386.6B+12.9%	$376.2B+13.0%	$366.0B+11.9%

Not reported in any period shown, so not listed: Current Assets, Inventory, Accounts Receivable, Current Liabilities, Non-Current Liabilities, Long-Term Debt.

AMJB Cash Flow Statement

AMJB quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	-$162.5B	-$147.8B-251.8%	-$42.0B-423.8%	$13.0B-87.9%	$107.1B+37.2%	$78.1B+197.7%	-$79.9B-2052.8%	$4.1B-73.8%	$15.6B+244.2%	-$10.8B-149.5%	$21.9B-70.2%	$73.5B+100.8%	$36.6B-66.1%	$108.0B+330.5%	$25.1B-73.9%	$95.9B
Depreciation & Amortization	N/A	$8.8B+11.1%	$7.9B+5.7%	$7.5B+6.5%	$7.1B-11.1%	$7.9B-7.9%	$8.6B+2.9%	$8.4B+7.4%	$7.8B+26.1%	$6.2B+12.8%	$5.5B+10.9%	$4.9B+3.8%	$4.8B-10.3%	$5.3B+3.1%	$5.1B+20.9%	$4.3B
Stock-Based Compensation	N/A	$3.6B+3.1%	$3.5B+12.4%	$3.1B+11.6%	$2.8B-4.6%	$2.9B+19.5%	$2.5B+8.6%	$2.3B-2.8%	$2.3B+12.2%	$2.1B+6.7%	$1.9B-2.4%	$2.0B-9.3%	$2.2B-1.3%	$2.2B-12.8%	$2.5B-4.9%	$2.7B
Investing Cash Flow	-$185.8B	-$265.6B-62.5%	-$163.4B-341.6%	$67.6B+149.1%	-$137.8B-6.6%	-$129.3B+50.6%	-$261.9B-403.1%	-$52.1B+73.9%	-$199.4B-805.9%	$28.2B+131.7%	-$89.2B-183.4%	$107.0B+164.6%	-$165.6B-10.1%	-$150.5B-25.6%	-$119.8B+29.8%	-$170.8B
Financing Cash Flow	$248.1B	$269.5B+324.8%	$63.4B+348.1%	-$25.6B+79.7%	-$126.3B-145.7%	$276.0B-53.7%	$596.6B+1708.7%	$33.0B-3.4%	$34.2B+133.3%	$14.6B-85.1%	$98.3B+152.4%	-$187.5B-258.6%	$118.2B+317.4%	$28.3B-67.7%	$87.7B-18.6%	$107.7B
Dividends Paid	$17.3B	$16.6B+12.5%	$14.8B+9.8%	$13.5B-0.7%	$13.6B+5.5%	$12.9B+1.3%	$12.7B+2.8%	$12.3B+22.1%	$10.1B+12.4%	$9.0B+6.1%	$8.5B+7.7%	$7.9B+12.6%	$7.0B+15.4%	$6.1B+16.6%	$5.2B+33.4%	$3.9B
Share Buybacks	$31.7B	$31.6B+67.8%	$18.8B+91.7%	$9.8B+210.7%	$3.2B-82.8%	$18.4B+182.5%	$6.5B-72.8%	$24.0B+20.1%	$20.0B+29.7%	$15.4B+69.7%	$9.1B+61.7%	$5.6B	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$25.3B-185.6%	-$211.8B+15.9%	$119.7B-19.0%	-$45.2B+39.0%	$29.5B-23.2%	-$251.8B-63.4%	$147.8B+145.3%	-$74.1B-264.2%
Depreciation & Amortization	$2.3B+4.8%	$2.4B+16.5%	$2.3B+17.7%	$2.3B+15.4%	$2.2B+10.4%	$2.0B+1.3%	$2.0B-41.1%	$2.0B-2.6%
Stock-Based Compensation	$1.2B+21.7%	$1.2B+11.4%	N/A	$910.0M+7.2%	$959.0M+1.6%	$1.1B+12.3%	N/A	$849.0M+8.6%
Investing Cash Flow	$6.4B+103.7%	-$217.8B-84.4%	$46.9B+166.1%	-$21.3B+50.9%	-$173.1B-83.6%	-$118.1B-172.2%	$17.6B-77.9%	-$43.4B-144.0%
Financing Cash Flow	$18.8B-84.7%	$400.7B+26.0%	-$123.6B-6.8%	-$47.8B-544.6%	$122.8B+350.9%	$318.1B+125.3%	-$115.7B-222.3%	$10.7B+349.0%
Dividends Paid	$4.3B+3.3%	$4.4B+14.4%	$4.4B+14.5%	$4.2B+14.4%	$4.2B+11.3%	$3.8B+9.4%	$3.9B+12.6%	$3.7B+7.9%
Share Buybacks	$6.8B-9.6%	$8.3B+10.6%	$8.3B+92.1%	$8.3B+30.4%	$7.5B+40.7%	$7.5B+165.8%	$4.3B+89.1%	$6.4B+167.0%

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow.

AMJB Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

AMJB quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Net Margin	31.2%-1.7pp	33.0%+1.6pp	31.4%+2.1pp	29.3%-10.4pp	39.7%+15.4pp	24.3%-7.2pp	31.5%+1.6pp	29.8%+5.6pp	24.3%-1.3pp	25.6%-0.5pp	26.1%+3.3pp	22.9%+4.5pp	18.4%-3.6pp	21.9%+2.4pp	19.5%
Return on Equity	15.7%-1.2pp	17.0%+1.8pp	15.1%+2.2pp	12.9%-3.5pp	16.4%+6.0pp	10.4%-3.5pp	13.9%+1.3pp	12.7%+3.1pp	9.6%-0.2pp	9.7%-0.1pp	9.9%+0.5pp	9.4%+0.9pp	8.5%-2.0pp	10.4%+0.1pp	10.3%
Return on Assets	1.3%-0.2pp	1.5%+0.2pp	1.3%+0.3pp	1.0%-0.3pp	1.3%+0.4pp	0.9%-0.5pp	1.4%+0.1pp	1.2%+0.3pp	1.0%0.0pp	1.0%0.0pp	1.0%+0.2pp	0.9%+0.1pp	0.7%-0.2pp	0.9%+0.1pp	0.8%
Debt-to-Equity	11.21+0.6x	10.61-0.2x	10.82-0.7x	11.54-0.2x	11.73+0.6x	11.12+1.8x	9.28+0.1x	9.22+0.3x	8.91+0.1x	8.80+0.3x	8.50-1.6x	10.10+8.8x	1.270.0x	1.22-0.2x	1.40
Asset Turnover	0.040.0x	0.040.0x	0.040.0x	0.040.0x	0.030.0x	0.040.0x	0.040.0x	0.040.0x	0.040.0x	0.040.0x	0.040.0x	0.040.0x	0.040.0x	0.040.0x	0.04

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Net Margin	36.9%+3.5pp	33.1%+0.8pp	28.3%-4.5pp	31.0%+0.8pp	33.4%-2.8pp	32.3%+0.3pp	32.8%+8.6pp	30.2%-2.7pp
Return on Equity	5.7%+1.4pp	4.5%+0.4pp	3.6%-0.5pp	4.0%+0.3pp	4.2%-1.1pp	4.2%+0.2pp	4.1%+1.2pp	3.7%-0.4pp
Return on Assets	0.4%+0.1pp	0.3%0.0pp	0.3%-0.1pp	0.3%0.0pp	0.3%-0.1pp	0.3%0.0pp	0.4%+0.1pp	0.3%0.0pp
Debt-to-Equity	12.39+0.6x	12.46+1.1x	11.21+0.6x	11.66+0.5x	11.75+0.6x	11.40+0.2x	10.61-0.2x	11.17-0.1x
Asset Turnover	0.010.0x	0.010.0x	0.010.0x	0.010.0x	0.010.0x	0.010.0x	0.010.0x	0.010.0x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Current Ratio, FCF Margin.

Where Alerian MLP Index ETNs due January 28 2044 Ranks

Frequently Asked Questions

What is Alerian MLP Index ETNs due January 28 2044's annual revenue?

Alerian MLP Index ETNs due January 28 2044 (AMJB) reported $182.4B in total revenue for fiscal year 2025. This represents a 2.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Alerian MLP Index ETNs due January 28 2044's revenue growing?

Alerian MLP Index ETNs due January 28 2044 (AMJB) revenue grew by 2.8% year-over-year, from $177.6B to $182.4B in fiscal year 2025.

Is Alerian MLP Index ETNs due January 28 2044 profitable?

Yes, Alerian MLP Index ETNs due January 28 2044 (AMJB) reported a net income of $57.0B in fiscal year 2025, with a net profit margin of 31.2%.

What is Alerian MLP Index ETNs due January 28 2044's net profit margin?

Alerian MLP Index ETNs due January 28 2044 (AMJB) had a net profit margin of 31.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Does Alerian MLP Index ETNs due January 28 2044 pay dividends?

Yes, Alerian MLP Index ETNs due January 28 2044 (AMJB) paid $5.80 per share in dividends during fiscal year 2025.

What is Alerian MLP Index ETNs due January 28 2044's return on equity (ROE)?

Alerian MLP Index ETNs due January 28 2044 (AMJB) has a return on equity of 15.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Alerian MLP Index ETNs due January 28 2044's operating cash flow?

Alerian MLP Index ETNs due January 28 2044 (AMJB) recorded an outflow of $147.8B in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Alerian MLP Index ETNs due January 28 2044's total assets?

Alerian MLP Index ETNs due January 28 2044 (AMJB) had $4.4T in total assets as of fiscal year 2025, including both current and long-term assets.

Does Alerian MLP Index ETNs due January 28 2044 buy back shares?

Yes, Alerian MLP Index ETNs due January 28 2044 (AMJB) spent $31.6B on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Alerian MLP Index ETNs due January 28 2044 have outstanding?

Alerian MLP Index ETNs due January 28 2044 (AMJB) had 2.70B shares outstanding as of fiscal year 2025.

What is Alerian MLP Index ETNs due January 28 2044's debt-to-equity ratio?

Alerian MLP Index ETNs due January 28 2044 (AMJB) had a debt-to-equity ratio of 11.21 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Alerian MLP Index ETNs due January 28 2044's return on assets (ROA)?

Alerian MLP Index ETNs due January 28 2044 (AMJB) had a return on assets of 1.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

How does Alerian MLP Index ETNs due January 28 2044's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Alerian MLP Index ETNs due January 28 2044 (AMJB) held $343.3B in cash, cash equivalents and investments, and reported an operating cash outflow of $147.8B over that year. Dividing the one by the other, the reported balance equals about 28 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Alerian MLP Index ETNs due January 28 2044's Piotroski F-Score?

Alerian MLP Index ETNs due January 28 2044 (AMJB) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Alerian MLP Index ETNs due January 28 2044's earnings high quality?

For every $1 of reported earnings, Alerian MLP Index ETNs due January 28 2044 (AMJB) used $2.59 of operating cash (-$147.8B OCF vs $57.0B net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Alerian MLP Index ETNs due January 28 2044 (AMJB) Financials

The reported accounts describe a highly leveraged financial vehicle, not a conventional operating business funded by sales and costs.

Financial Health Signals

Key Financial Metrics

Earnings & Revenue

Cash & Balance Sheet

Margins & Returns

Capital Allocation

AMJB Income Statement

AMJB Balance Sheet

AMJB Cash Flow Statement

AMJB Financial Ratios

Where Alerian MLP Index ETNs due January 28 2044 Ranks

Frequently Asked Questions

What is Alerian MLP Index ETNs due January 28 2044's annual revenue?

How fast is Alerian MLP Index ETNs due January 28 2044's revenue growing?

Is Alerian MLP Index ETNs due January 28 2044 profitable?

What is Alerian MLP Index ETNs due January 28 2044's earnings per share (EPS)?

What is Alerian MLP Index ETNs due January 28 2044's net profit margin?

Does Alerian MLP Index ETNs due January 28 2044 pay dividends?

What is Alerian MLP Index ETNs due January 28 2044's return on equity (ROE)?

What is Alerian MLP Index ETNs due January 28 2044's operating cash flow?

What are Alerian MLP Index ETNs due January 28 2044's total assets?

Does Alerian MLP Index ETNs due January 28 2044 buy back shares?

How many shares does Alerian MLP Index ETNs due January 28 2044 have outstanding?

What is Alerian MLP Index ETNs due January 28 2044's debt-to-equity ratio?

What is Alerian MLP Index ETNs due January 28 2044's return on assets (ROA)?

How does Alerian MLP Index ETNs due January 28 2044's liquidity compare with its operating cash outflow?

What is Alerian MLP Index ETNs due January 28 2044's Piotroski F-Score?

Are Alerian MLP Index ETNs due January 28 2044's earnings high quality?